Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Biochimica et Biophysica Acta

• Publication date

  1994-12-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0167-4838(94)90184-8PMID 7811690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1.

  1994cited by this paper
• Urokinase-type plasminogen activator and malignancy

  1993cited by this paper
• Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods.

  1993cited by this paper
• Antigen-antibody binding and mass transport by convection and diffusion to a surface: a two-dimensional computer model of binding and dissociation kinetics.

  1993cited by this paper
• Kinetic differentiation between enzyme inactivation involving complex-formation with the inactivator and that involving a conformation-change step.

  1992cited by this paper
• Structure and mechanism of action of serpins.

  1992cited by this paper
• Analysis of macromolecular interactions using immobilized ligands.

  1992cited by this paper
• The plasminogen activator inhibitor-1 binding site in the kringle-2 domain of tissue-type plasminogen activator.

  1991cited by this paper
• On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.

  1991cited by this paper
• Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins

  1991cited by this paper
• High resolution analysis of functional determinants on human tissue-type plasminogen activator.

  1991cited by this paper
• Tissue plasminogen activator mutants lacking the growth factor domain and the first kringle domain: I: DNA Constructions, Expression in Mammalian Cells, Protein Structure, Fibrin Affinity and Enzymatic Properties

  1991cited by this paper
• Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.

  1990cited by this paper
• Conformational differences between latent and active plasminogen activator inhibitor, PAI-1: a spectroscopic study.

  1990cited by this paper
• The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

  1990cited by this paper
• Characterization of Monoclonal Antibodies to Human Tissue-Type Plasminogen Activator: Catalytic Inhibition and One-Two Chain Discriminatory Reactivities

  1989cited by this paper
• Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.

  1989cited by this paper
• Serpin-resistant mutants of human tissue-type plasminogen activator

  1989cited by this paper
• Genetic engineering and the serpins.

  1988cited by this paper
• Neutralization by plasminogen activator inhibitor-1 of mutants of tissue plasminogen activator.

  1988cited by this paper
• Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.

  1988cited by this paper
• Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions.

  1988cited by this paper
• The molecular basis of blood coagulation.

  1988cited by this paper
• Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator.

  1987cited by this paper
• ACTIVATION OF HUMAN ENDOTHELIAL TYPE PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) BY NEGATIVELY CHARGED PHOSPHOLIPIDS

  1987cited by this paper
• Identification of the plasminogen-binding site of human alpha 2-plasmin inhibitor.

  1986cited by this paper
• Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.

  1986cited by this paper
• Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.

  1986cited by this paper
• Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules.

  1985cited by this paper
• Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.

  1985cited by this paper
• On the Composition and Function of the Carbohydrate Moiety of Tissue-Type Plasminogen Activator from Human Melanoma Cells

  1985cited by this paper
• Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences.

  1984cited by this paper
• Purification and characterization of a melanoma cell plasminogen activator.

  1983cited by this paper
• Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

  1983cited by this paper
• Solution composition dependent variation in extinction coefficients for p-nitroaniline.

  1983cited by this paper
• Studies on the kinetics of plasminogen activation by tissue plasminogen activator.

  1982cited by this paper
• Enzymatic properties of the one- and two-chain form of tissue plasminogen activator.

  1982cited by this paper

• Tranexamic Acid for Prevention of Hemorrhage in Elective Repeat Cesarean Delivery - A Randomized Study.

  2022cites this paper
• Hemorrhagic shock and tissue injury provoke distinct components of trauma-induced coagulopathy in a swine model

  2022cites this paper
• Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products

  2019cites this paper
• tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity

  2018cites this paper
• Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients

  2016cites this paper
• Aspects of Plasminiogen Activator Inhibitor 1 in Metabolic Syndrome

  2016cites this paper
• The role of leptin in endothelial dysfunction and cardiovascular disease

  2013cites this paper
• Characterization of a Small Molecule Inhibitor of Plasminogen Activator Inhibitor Type 1 That Accelerates the Transition into the Latent Conformation*

  2012cites this paper
• Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases

  2012cites this paper
• Basic Science Advances for Clinicians

  2011cites this paper
• ADIPOCYTE-DERIVED HORMONES AND CARDIOVASCULAR DISEASE

  2010cites this paper
• Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.

  2010cites this paper
• Plasminogen Activator Inhibitor 1 in Platelets - Studies of Synthesis, Activity, and Glycosylation Patterns

  2008cites this paper
• Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin.

  2008cites this paper
• Characterization of a small molecule PAI-1 inhibitor, ZK4044.

  2005cites this paper
• Protonation State of a Single Histidine Residue Contributes Significantly to the Kinetics of the Reaction of Plasminogen Activator Inhibitor-1 with Tissue-type Plasminogen Activator*

  2004cites this paper
• The interaction between captured human thrombin and antithrombin studied by surface plasmon resonance, and the effect of melagatran

  2002cites this paper
• Acute Phase Protein α1-Acid Glycoprotein Interacts with Plasminogen Activator Inhibitor Type 1 and Stabilizes Its Inhibitory Activity*

  2001cites this paper
• Purification of soluble and membrane-bound proteases with substrate-analogous inhibitors by affinity chromatography.

  2001cites this paper
• Characterization of the interaction of plasminogen activator inhibitor type 1 with vitronectin by surface plasmon resonance

  2000cites this paper
• Protein movement during complex-formation between tissue plasminogen activator and plasminogen activator inhibitor-1.

  1999cites this paper
• Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.

  1998cites this paper
• Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.

  1998cites this paper
• Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.

  1998cites this paper
• Comparison of chromogenic substrates for tissue plasminogen activator and the effects on the stability of plasminogen activator inhibitor type-1

  1997cites this paper
• Assessment of the Interaction Between Urokinase and Reactive Site Mutants of Protein C Inhibitor

  1997cites this paper
• The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin.

  1997cites this paper
• Detergent tween 80 modifies the specific activity of PAI-1

  1997cites this paper
• Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator.

  1997cites this paper
• Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography.

  1996cites this paper
• Characterization of receptors interacting specifically with the B-chain of tissue plasminogen activator on endothelial cells

  1996cites this paper
• Evaluation of a Low Molecular Weight Modulator of Human Plasminogen Activator Inhibitor-1 Activity

  1996cites this paper